The European Patent Office (EPO) has granted patent EP3366126B1, titled 'Transgenic mice expressing human lambda immunoglobulin light chain variable domains'. This patent, effective March 18, 2026, covers specific genetic modifications in mice for the production of human antibodies, which is a key development in the field of biopharmaceuticals.

While this is a patent grant and not a regulatory rule imposing direct compliance obligations on companies, it signifies intellectual property protection for a specific technology. Companies operating in the biotechnology and pharmaceutical sectors, particularly those involved in antibody research and development, should be aware of this patent's existence and scope. It may impact freedom to operate and licensing strategies for related research or commercialization activities.